<i>BRAF</i> and <i>NRAS</i> Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma

Abstract

Ipilimumab-nivolumab-treated patients with <i>BRAF</i>-mutant melanoma display improved PFS and OS compared with patients with <i>NRAS</i>-mutant and double wild-type melanoma. <i>BRAF</i> mutation status is a factor to consider while choosing between mono and dual checkpoint inhibition in advanced melanoma.